title: The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma.
abstract: Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.
authors.forename: Geoffrey L
authors.initials: GL
authors.lastname: Uy
authors.forename: Michael H
authors.initials: MH
authors.lastname: Tomasson
authors.forename: Alisa
authors.initials: A
authors.lastname: Ruddell
authors.forename: John F
authors.initials: JF
authors.lastname: DiPersio
authors.forename: Ravi
authors.initials: R
authors.lastname: Vij
mesh_terms: D000227:Adenine Nucleotides / Q000008:administration & dosage* / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D001087:Arabinonucleosides / Q000008:administration & dosage* / Q000009:adverse effects*; D000077866:Clofarabine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy*; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced
chemical_list: D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D000077866:Clofarabine